Advancing Medicines Quality Assurance Systems in LMICs: Celebrating 10 Years of PQM Program Achievements

June 27, 2019
Crystal Gateway Marriott, Arlington, VA

Opening Remarks
Susan Winckler, Chair, USP Board of Trustees

- Through the PQM program, we have seen major accomplishments in improving the quality of essential medicines in LMICs, as a result of stronger regulatory systems and expanded capacities for quality assurance from the time a medicine is made until it reaches the patient.
- USP is committed to building on these accomplishments and complementing donor investments in quality assurance system strengthening—and we are uniquely positioned to do so.
- As part of this commitment, we will leverage USP’s core strengths of convening the world’s best experts and our standards-development processes to:
  - Expand our technology review initiative that helps countries make informed decisions about which field-based screening technologies best meet their situation—a need we recognized based on our experience with the PQM program.
  - Continue developing global health standards for essential public health medicines.
- We will also continue our investment in advancing the science of quality, including:
  - The USP Quality Institute, which partners with universities to provide much-needed research about the role of quality medicines in public health, including efforts to curb antimicrobial resistance...
  - USP’s work in research and innovation, which investigates emerging technologies that can inform standards development, including new types of testing methods and manufacturing processes, such as pharmaceutical continuous manufacturing.
- We are mindful that all of this important work began with the opportunity presented by the U.S. Agency for International Development (USAID). We are grateful to USAID for what we’ve been able to accomplish together and for how we have grown as a result.